revvity

Discovery extended with high quality, actionable data

Cell panel screening services

High-throughput Cell Panel Screening is a key drug development tool for identifying sensitive or resistant tumor types and genomic features governing response. Revvity's 15 years of experience in high-throughput phenotypic screening and drug profiling across large panels of cancer cell lines can provide efficacy and toxicity data on your lead oncology therapeutics.

- Study drug response by identifying sensitive and resistant cells.
- Aid patient stratification for your drug candidate or drug combination.
- Bioinformatics analysis for linking molecular features with phenotypic response.

LEARN MORE

For more information, visit us at:
horizondiscovery.com/en/screening/cell-panel-screening



2D and 3D OncoSignature™ cell panel screening

Reveal the efficacy and antiproliferative signature of your small molecules or biologics as single agents or combinations across an extensive panel of 2D cancer cell line models.

Complement two-dimensional screening approaches with high-throughput 3D assays for improved modeling of mechanical, biochemical and cell-to-cell signaling of the 3D tumor micro-environment for enhanced predictions of clinical response.

The 2D and 3D OncoSignature™ screening offerings are run on a continual cycle with monthly data deliveries to allow for flexible onboarding and compound submission.

Screen across a diverse, clinically relevant 200 (3D) or 300 (2D) cell line panel or a more focused, tissue-specific panel such as lung, lymphoma, head and neck, or breast.

- Study drug response by identifying sensitive and resistant cells.
- Aid patient stratification for your drug candidate or drug combination.
- Bioinformatics analysis for linking molecular features with phenotypic response.
- Identify single agent efficacy or combination interactions with our proprietary Chalice™ software developed to provide collaborators with the same proven analysis tools employed by Revvity in our existing research programs.

Long-term cell panel screening

A long-term (10-day) high-throughput cell panel screening assay developed to study the prolonged effects of slower acting agents and epigenetic targets.

Revvity has extensively optimized assay conditions to overcome typical challenges of overgrowth and nutrient depletion associated with miniaturized, automation-based workflows to provide greater resolution of cellular response profiles over an extended assay window.

- An extensive panel of 248 solid tumor cell lines.
- High cell quality and a robust and standardized cell seeding process for consistent and reproducible experimental results.
- Sufficient 10 day assay signal to indicate optimal cell growth and viability with extended duration.
- Good technical reproducibility and dose response curves.

Large enhancer combination screening services

Screen large numbers of therapeutic agents to discover novel combination pairings that boost the therapeutic profile of a lead drug and enhance treatment outcomes.

- Select cell lines from an extensive panel of 600+ solid and hematological tumor lines.
- Design an enhancer panel with a curated list of oncology focused SOCs, emerging therapeutics and well defined molecular probes.
- Multi-phase screening with a monotherapy dose optimizing phase for precise combination screen design and data interpretation.
- Identify synergistic and antagonistic pathway interactions to optimize treatment strategies.
- Leverage extensive combination screening experience and expertise to aid in effective study design, data interpretation and hit prioritization.



Slower acting inhibitor classes (PARP and EZH2 inhibitors) have greater responses in the 10-day Long-Term Assay (shift to right along X axis, as indicated by arrows) compared to the standard 6-day assay. Responses for a faster acting therapeutic (WEE1i) were generally similar (points distributed along X=Y line indicating equal response at 6-days and 10-days).



Compound responses in 2D versus 3D: Enhanced sensitvity to single agent MEK and EGFR inhibition or combined suppression of the MEK and PI3K pathways in 3D. Representative does response curve (A) and dose matrices for combined dosing of GDC-0941 (Pictilisib) and Trametinib in 2D and 3D (B).

Revvity, Inc.
940 Winter Street
Waltham, MA 02451 USA

(800) 762-4000
www.revvity.com

For a complete listing of our global offices, visit www.revvity.com